CBL-LOH JMML is generally less aggressive clinically than JMML driven by other RAS pathway genes (NRAS, KRAS, PTPN11, and NF1), often resolving spontaneously (26). This evidence concerns the gene KRAS and juvenile myelomonocytic leukemia.